Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | ULK1 | O75385 | 3/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15937904 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14737719 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14738047 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14738295 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2102188 | 0.98 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2102190 | 0.98 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2102193 | 0.98 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL15542335 | 0.85 | — | — | |
| SCHEMBL1316373 | 0.85 | — | — | |
| SCHEMBL4701745 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| EP-2016047-B1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | claimed |
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-06-13 | — | — | US | claimed |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | claimed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | claimed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | claimed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP4K2, MAP3K19 | KDM4E 748/4885MAPT 2140/4885KMT2A 2790/4885 |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | KDM4E 2530/4885MAPT 2815/4885KMT2A 3992/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | KDM4E 2471/4885MAPT 2262/4885KMT2A 1941/4885 |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | KDM4E 1143/4885MAPT 2668/4885KMT2A 1020/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | KDM4E 2471/4885MAPT 2262/4885KMT2A 1941/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | KDM4E 2471/4885MAPT 2262/4885KMT2A 1941/4885 |
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | KDM4E 3857/4885MAPT 291/4885KMT2A 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.